244 related articles for article (PubMed ID: 32379508)
1. LSD1: a viable therapeutic target in cutaneous squamous cell carcinoma?
Egolf S; Capell BC
Expert Opin Ther Targets; 2020 Jul; 24(7):671-678. PubMed ID: 32379508
[TBL] [Abstract][Full Text] [Related]
2. LSD1 Inhibition Promotes Epithelial Differentiation through Derepression of Fate-Determining Transcription Factors.
Egolf S; Aubert Y; Doepner M; Anderson A; Maldonado-Lopez A; Pacella G; Lee J; Ko EK; Zou J; Lan Y; Simpson CL; Ridky T; Capell BC
Cell Rep; 2019 Aug; 28(8):1981-1992.e7. PubMed ID: 31433976
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
Przespolewski A; Wang ES
Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
[TBL] [Abstract][Full Text] [Related]
4. LSD1: biologic roles and therapeutic targeting.
Maiques-Diaz A; Somervaille TC
Epigenomics; 2016 Aug; 8(8):1103-16. PubMed ID: 27479862
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
Hosseini A; Minucci S
Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
[TBL] [Abstract][Full Text] [Related]
6. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
Zhang S; Liu M; Yao Y; Yu B; Liu H
Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
[TBL] [Abstract][Full Text] [Related]
7. LSD1 inhibition: a therapeutic strategy in cancer?
Lynch JT; Harris WJ; Somervaille TC
Expert Opin Ther Targets; 2012 Dec; 16(12):1239-49. PubMed ID: 22957941
[TBL] [Abstract][Full Text] [Related]
8. The histone demethylase LSD1 is a novel oncogene and therapeutic target in oral cancer.
Wang Y; Zhu Y; Wang Q; Hu H; Li Z; Wang D; Zhang W; Qi B; Ye J; Wu H; Jiang H; Liu L; Yang J; Cheng J
Cancer Lett; 2016 Apr; 374(1):12-21. PubMed ID: 26872725
[TBL] [Abstract][Full Text] [Related]
9. Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021.
Song Y; Zhang H; Yang X; Shi Y; Yu B
Eur J Med Chem; 2022 Jan; 228():114042. PubMed ID: 34915312
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic regulatory mechanisms of histone acetylation in the treatment of cutaneous squamous cell carcinoma.
Joshi TP; Farr MA; Lewis DJ
Expert Opin Ther Targets; 2021 Nov; 25(11):1025-1026. PubMed ID: 34814792
[TBL] [Abstract][Full Text] [Related]
11. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
[TBL] [Abstract][Full Text] [Related]
12. Melatonin exerts anti-oral cancer effect via suppressing LSD1 in patient-derived tumor xenograft models.
Yang CY; Lin CK; Tsao CH; Hsieh CC; Lin GJ; Ma KH; Shieh YS; Sytwu HK; Chen YW
Oncotarget; 2017 May; 8(20):33756-33769. PubMed ID: 28422711
[TBL] [Abstract][Full Text] [Related]
13. LSD1 inhibition induces differentiation and cell death in Merkel cell carcinoma.
Leiendecker L; Jung PS; Krecioch I; Neumann T; Schleiffer A; Mechtler K; Wiesner T; Obenauf AC
EMBO Mol Med; 2020 Nov; 12(11):e12525. PubMed ID: 33026191
[TBL] [Abstract][Full Text] [Related]
14. LSD1/KDM1A inhibitors in clinical trials: advances and prospects.
Fang Y; Liao G; Yu B
J Hematol Oncol; 2019 Dec; 12(1):129. PubMed ID: 31801559
[TBL] [Abstract][Full Text] [Related]
15. Annual review of LSD1/KDM1A inhibitors in 2020.
Fu DJ; Li J; Yu B
Eur J Med Chem; 2021 Mar; 214():113254. PubMed ID: 33581557
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
[TBL] [Abstract][Full Text] [Related]
17. Lysine-specific demethylase 1 as a therapeutic cancer target: observations from preclinical study.
Johnson JD; Alejo S; Jayamohan S; Sareddy GR
Expert Opin Ther Targets; 2023; 27(12):1177-1188. PubMed ID: 37997756
[TBL] [Abstract][Full Text] [Related]
18. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
[TBL] [Abstract][Full Text] [Related]
19. Target separation and antitumor metastasis activity of sesquiterpene-based lysine-specific demethylase 1 inhibitors from zedoary turmeric oil.
Ren C; Lin Y; Liu X; Yan D; Xu X; Zhu D; Kong L; Han C
Bioorg Chem; 2021 Mar; 108():104666. PubMed ID: 33550070
[TBL] [Abstract][Full Text] [Related]
20. Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.
Haydn T; Metzger E; Schuele R; Fulda S
Cell Death Dis; 2017 Jun; 8(6):e2879. PubMed ID: 28617441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
